Akeso?is committed to developing first-in-class?and best-in-class?new?drugs through efficient and groundbreaking R&D innovation. Since its establishment, the Company?has been committed to building fully?integrated internal development capabilities. An end-to-end drug development platform, the Akeso?Comprehensive Exploration Platform (ACE Platform),?has been?developed?with great foresight, encompassing?functionalities including?drug target validation, antibody discovery and preclinical study, CMC manufacturing process development and GMP-compliant commercialization?production.
?
The ACE platform runs through the full life cycle of drug candidates through development to production and commercialization, and reducing our reliance on the external service system. In addition,it ensures and promote the efficient operation of the new drug development process, thereby increasing the possibility of success rate and reducing the development cost. Based on this platform, we have developed over 50 innovative drug candidates with fully independent intellectual property rights, focusing on major diseases such as tumors and autoimmune, inflammatory and metabolic diseases. Among them, 22 drug candidates have entered clinical strage, with their production processes being developed by the internal platform.
Tetrabody technology is a proprietary technology independently developed by Akeso?for the design and manufacture of innovative tetravalent bispecific antibodies. It?overcomes CMC challenges such as low expression levels due to the high molecular weight of bispecific antibodies, process development obstacles?due to?the structural heterogeneity of bispecific antibodies, and non-druggability due to the lack of stability of bispecific antibodies.
?
Using our unique Tetrabody technology, we have successfully developed 11+ innovative, world-leading bispecific antibody,multi-specific antibody and BsAb ADC drugs, including开坦尼? (PD-1/CTLA-4 bispecific antibody, Cadonilimab injection),依达方??(PD-1/VEGF bi-specific antibody,Ivonescimab injection) and AK130,etc. 开坦尼? is?the world's first commercialized dual immune checkpoint inhibitor bispecific antibody to treat cancer.? 依达方?? is the world's first PD-1/VEGF bispecific antibody drug; and AK130 is the world's first and only TIGIT/TGF-β dual-targeting antibody fusion protein in research. This results fully demonstrate the strength of Akeso's innovative development strength and its leading position in the field of bispecific antibodies.
?
In order to effectively improve the efficacy?of antibody drug therapy and develop more and better therapies?for patients worldwide, Akeso?actively explores treatment regimens such as combining?chemotherapy and targeted drugs. Bispecific antibodies can block the biological functions mediated by two antigens/epitopes simultaneously, and are expected to induce potential superior biological effects that have never been achieved?by?single-target antibodies, giving the?combination of targeted therapy and chemotherapy?broad prospects. We believe some of our?commercialized drugs?and drug?candidates have the potential to be the?backbone?drugs of?combination?therapies.
?
Akeso is vigorously promoting research on bispecific antibody-based combination therapies and pushing tumor immunotherapy into the era?of 2.0 . As of the end of 2022, a total of 33 combination?therapies based on bispecific antibodies had been effectively ?implemented. Based on Cadonilimab?and?Ivonescimab, the exploration of combination?therapies?with many self-developed products or other drugs has shown promising synergies, and is expected to provide patients?with?superior?therapeutic benefit. The social and industrial value of Akeso's innovative drugs?will be fully presented in this development strategy.